RBC Says Tekmira Pharmaceuticals Corporation (TKMR) Hype Missing The Point

As the roller coaster ride that is the Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) stock continues, the Royal Bank of Canada (NYSE:RY) (TSE:RY) is out with a new report that seems to suggest investors are missing the point.

Tekmira’s Hepatitis B cure is the real value

The RBC research report shouts the headline that while the Ebola scare, and Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)’s cure for the health epidemic, is in the headlines, it is the firm’s Hepatitis B cure that is the real value.

The report says that even given the near 80 percent rise then subsequent retracement, Tekmira remains undervalued due to the upside potential of the firm’s Hepatitis treatment, TKM-HBV.  The Tekmira...